Cambridge Healthtech Institute’s 6th Annual

Accelerating Target Discovery

Advanced Genomics, Chemical Biology & Targeted Degradation Technologies

June 2-4, 2020


Finding novel, druggable targets for therapeutic intervention remains a top priority for the pharma/biotech industry. It also remains a formidable challenge, and companies continue to invest a lot of time and resources into identifying and validating targets that will yield viable drugs. What are the current challenges? What new tools and strategies are being developed to address those challenges and how well are they working? What’s being done to adequately deconvolute, validate and prioritize the targets once they are identified? What’s being done to go after difficult or “undruggable” targets? Cambridge Healthtech Institute’s conference on Accelerating Target Discovery will bring together leading experts to discuss some of these critical questions. This is a unique opportunity for biologists and screening experts to come together to share ideas and best practices, and find a way to populate the drug pipeline with novel, well-characterized drug targets.

EXPLORING advanced genomics

CRISPR Screening for Target and Off-Target Identification
Jason Sheltzer, PhD, Principal Investigator, Cold Spring Harbor Laboratory

Case Studies: Using Targeted and Genome-wide CRISPR Screens for Drug Target and Pathway Analysis
Michael Bassik, PhD, Assistant Professor, Department of Genetics, Stanford University

Multiscale Network Biology Approach to Identify Novel Targets of Parkinson’s Disease
Bin Zhang, PhD, Professor, Department of Genetics & Genomic Sciences; Director, Mount Sinai Center for Transformative Disease Modeling, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai

FINDING NEW TARGETS FOR CANCER IMMUNOTHERAPY

Deeper, Finer, and Wider with CRISPR Screens for Gene Function
John Doench, PhD, Director R&D, Genetic Perturbation Platform, Broad Institute of Harvard and Massachusetts Institute of Technology (MIT)

In vivo T Cell CRISPR Screen for Immunotherapy Target Discovery
Sidi Chen, PhD, Assistant Professor, Department of Genetics and Systems Biology Institute, Yale University; Member, Yale Cancer Center and the Yale Stem Cell Center

EXPLOITING CHEMICAL BIOLOGY & PHENOTYPIC SCREENING

Application of Chemical Biology Probes and Bioorthogonal Chemistry in Drug Discovery 

Doug Johnson, PhD, Senior Director, Chemical Biology & Proteomics, Biogen

Design of Photoaffinity and Electrophilic Probes for Target Identification and Validation 

Christopher am Ende, Senior Principal Scientist, Pfizer Inc.

Small Molecule Phenotypic Screening: Biological Tools, Novel Targets or Leads?
Sujatha Gopalakrishnan, PhD, Head, Molecular Screening and Characterization, AbbVie

SINGLE CELL TECHNOLOGIES FOR TARGET DISCOVERY

Pooled CRISPR Screens with Single-Cell Chromatin Accessibility Profiling
Neville Sanjana, PhD, Assistant Professor, Departments of Neuroscience and Physiology, New York University; Faculty, New York Genome Center

The State of the Art in Highly Multiplexed Multi in situ OMICs
Richie Kohman, PhD, Senior Research Scientist and Lead, Synthetic Biology Platform, Wyss Institute for Biologically Inspired Engineering, Harvard University

EMERGING TOOLS FOR TARGET DECONVOLUTION & PATHWAY ANALYSIS

AI-Assisted Therapeutic Drug Screening System
Wenjin Zhou, PhD, Assistant Professor, Department of Computer Science, University of Massachusetts Lowell

Gating and Drug Modulation in 5-HT3A Receptor: Insights from Cryo-EM
Sandip Basak, PhD, Post-Doctoral Fellow, Laboratory of Dr. Sudha Chakrapani, Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University

STRATEGIES FOR TARGET ENGAGEMENT AND DEGRADATION

Large Scale Proteomics Approaches to Enable Degrader Development for Challenging Targets in Cancer
Katherine Donovan, PhD, Scientist, Laboratory of Dr. Eric Fischer, Cancer Biology, Dana-Farber Cancer Institute/Harvard Medical School

Targeting Tauopathy with Engineered Tau-Degrading Intrabodies
Gilbert Gallardo, PhD, Assistant Professor, Hope Center for Neurological Disorders, Washington University School of Medicine

Discovery of Bcl-xL Degraders: A PROTAC Strategy for Tissue Selective Targeting
Guangrong Zheng, PhD, Associate Professor, Department of Medicinal Chemistry, College of Pharmacy, University of Florida